Here’s why the Imugene share price just got a boost

Imugene’s latest announcement is rallying up investors.

| More on:
Person pointing at an increasing blue graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares surge 4.24% to 17.2 cents 
  • The company has dosed its first patient in the phase 1 clinical trial of oncolytic virus, CF33-hNIS 
  • The study is aiming to recruit 100 patients across 10 trial sites in the United States and Australia 

The Imugene Limited (ASX: IMU) share price has shot up during early afternoon trade.

This comes after the company announced an update on its phase 1 clinical trial of its novel cancer-killing virus, CF33-hNIS.

Developed by City of Hope, the oncolytic virus has demonstrated in shrinking solid tumours in preclinical laboratory and animal trials. This includes colon, lung, breast, ovarian and pancreatic cancer tumours.

City of Hope is one of the largest cancer research and treatment organizations in the United States.

At the time of writing, the clinical stage immuno-oncology company’s shares are 4.24% higher to 17.2 cents.

Imugene commences Vaxinia study

In its release, Imugene advised it has dosed the first patient in the phase 1 clinical trial of CF33-hNIS (Vaxinia).

This has stirred up excitement among investors, sending the Imugene share price higher.

Management noted the primary goal of the study is to evaluate the safety of CF33-hNIS when used in people with advanced solid tumours.

At first, a low dose of CF33-hNIS will be administered to cancer patients with metastatic or advanced solid tumours. This will be for those who have had at least two prior lines of standard of care treatment.

The investigational treatment will be delivered either as an injection directly into tumours or intravenously.

Once patients have been treated with CF33-hNIS and acceptable safety has been demonstrated, new study participants will progress to the next stage.

Those volunteers will receive the experimental oncolytic virus in combination with the immunotherapy pembrolizumab. The latter is an engineered antibody that improves the immune system’s ability to fight cancer-causing cells.

The study aims to recruit 100 patients across approximately 10 sites in the United States and Australia.

The trial is anticipated to run for approximately 24 months and will be funded from Imugene’s existing cash reserves.

Imugene managing director and CEO Leslie Chong commented:

The dosing of the first patient in our Vaxinia study is a significant milestone for Imugene and clinicians faced with the challenge of treatment for metastatic advanced solid tumours.

Professor Yuman Fong and the City of Hope team have provided outstanding research. In addition to the positive preclinical results, we’re incredibly eager to unlock the potential of Vaxinia and the oncolytic virotherapy platform.

Imugene share price snapshot

Despite today’s gains, the Imugene share price has been on a trending decline over the past 12 months. Its shares are down almost 50%, with year to date losses of around 57%.

The company’s shares hit a 52-week low of 15 cents last week, before moving in circles.

Based on the current price, Imugene has a market capitalisation of roughly $965.05 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Healthcare Shares

What was the Sonic Healthcare share price when it first listed on the ASX?

Sonic Healthcare has an interesting history...

Read more »

asx share penalty represented by lots of fingers pointing at disgraced businessman Crown royal commission WA
Share Market News

Melbourne man jailed for insider trading of ASX shares

Former executive of a listed company sentenced after selling his stocks while aware of information that the public was not…

Read more »

Happy healthcare workers in a labs
Healthcare Shares

‘Significant milestone’: Why the Imugene share price is soaring 30% today

What's driving the Imugene share price higher today?

Read more »

medical imaging doctor amid images of human brains
Healthcare Shares

The Pro Medicus share price is down 30% in 2022. Is it a buy?

This ASX share has a very high profit margin. But after the volatility, is an opportunity?

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why this broker is tipping ‘strength in the CSL share price’

A leading broker is feeling positive about the CSL share price...

Read more »